NCT00038597已完成2 期
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 2
研究概览
简要总结
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.
详细描述
Objectives for this study are two-fold:
- To determine the efficacy of SCH66336 in patients with chronic phase and accelerated phase CML in relation to response rate, duration of response, and survival.
- To assess the toxicity of SCH66366 in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell CancerCarcinoma, Squamous CellCancer of Head and NeckNCT00038584M.D. Anderson Cancer Center37
已完成
1 期
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasGliosarcomaAnaplastic AstrocytomaGlioblastomaNCT00612651Duke University37
Unknown
1 期
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)CancerNCT00006199National Center for Research Resources (NCRR)
已完成
1 期
SCH 66336 in Treating Children With Recurrent or Progressive Brain TumorsBrain and Central Nervous System TumorsNCT00015899Pediatric Brain Tumor Consortium53
终止
1 期
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Gastrointestinal Stromal Tumors (GIST)Neoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsGastrointestinal NeoplasmsDigestive System DiseaseGastrointestinal DiseasesDigestive System NeoplasmNCT05160168Theseus Pharmaceuticals32